Gene expression profiling identified TP53^MutPIK3CA^Wild as a potential biomarker for patients with triple-negative breast cancer treated with immune checkpoint inhibitors.

ABSTRACT: Triple-negative breast cancer (TNBC) accounts for 15-30% of all breast cancer cases and is clinically difficult to treat due to the lack of hormone or human epidermal growth factor receptor 2 receptors, which are usually targeted by the most successful therapeutic approaches. Immune checkpoint inhibitors (ICIs) have offered long-term survival benefits in several types of solid tumors, however with low response rates. Thus, there is an urgent need to develop feasible biomarkers for identifying patients with TNBC, who are responsive. The present study demonstrated that the immune microenvironment of TNBC has the highest expression of immunoregulatory molecules among all pathologic types. The tumor mutation burden (TMB) of TNBC was not strongly correlated with cytolytic activity and showed no

SUBMITTER: Cheng J 

PROVIDER: S-EPMC7068237 | biostudies-literature | 2020 Apr

REPOSITORIES: biostudies-literature